ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany)

Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline J. Froehlich (Hayward, United States of America)
Prolonged effect of air pollution on pneumonia: a nationwide cohort study W. Ji (Seoul, Republic of Korea)
Time to Blood Culture Positivity as a Predictor of Clinical Outcomes and Severity in Adults with Bacteremic Pneumococcal Pneumonia C. Cilloniz Campos (Barcelona, Spain)
Admission lactate predicts poor prognosis independently of the CRB/CURB-65 scores in community-acquired pneumonia. M. Kolditz (Dresden, Germany)
Oxy-Met score: a new physiological index to predict mortality in community-acquired pneumonia F. Sanz Herrero (Quart de Poblet (Valencia), Spain)
Risk factors associated with “PES pathogens” in community-onset pneumonia: 16S rRNA gene analysis of BALF. T. Kawanami (Kitakyushu City, Japan)
Azithromycin is associated with improved survival in patients with healthcare-associated pneumonia E. Mortensen (Simsbury, United States of America)
Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP? A. Ceccato (Ituzaingo, Buenos Aires, Argentina)